Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases the amount of acid produced in the stomach.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Duodenal ulcers
* H. pylori eradication (in combination with antibiotics)
## Adult Dosing
* **GERD:** 20-40 mg orally or intravenously once daily.
* **Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. Maintenance therapy: 20-40 mg orally once daily.
* **Hypersecretory Conditions:** Starting dose typically 40 mg orally or intravenously twice daily. Doses may be increased as needed. Maximum dose: 240 mg daily.
* **Duodenal Ulcers:** 40 mg orally once daily for up to 4 weeks.
* **H. pylori Eradication:** 40 mg orally twice daily for 7-14 days in combination with clarithromycin and amoxicillin, or with clarithromycin and metronidazole.
## Pediatric Dosing
Dosing in pediatric patients varies significantly by age and indication. Consult specific pediatric guidelines or manufacturer information.
* **Erosive Esophagitis (ages 5-16 years):** 20-40 mg orally once daily.
* **GERD (ages 5-16 years):** 20-40 mg orally once daily.
## Dose Adjustments
No dose adjustment is typically required for hepatic or renal impairment. However, caution may be advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Use of rilpivirine-containing products.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use may be associated with an increased risk of:
* Fractures (hip, wrist, spine)
* Clostridium difficile infection
* Hypomagnesemia
* Vitamin B12 deficiency
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, iron salts, mycophenolate mofetil. Pantoprazole can decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates/inhibitors:** Pantoprazole is a moderate inhibitor of CYP2C19. Monitor for potential interactions.
* **Rilpivirine:** Coadministration is contraindicated due to risk of virologic failure.
* **Clopidogrel:** Pantoprazole may reduce the antiplatelet effect of clopidogrel. Consider the risks and benefits.
## Monitoring
* Assess for improvement of GERD symptoms.
* Monitor for signs and symptoms of C. difficile-associated diarrhea.
* Consider monitoring magnesium levels in patients on long-term therapy, especially those taking concomitant diuretics or digoxin.
* Monitor for signs of bone fracture.
## Clinical Pearls
* Pantoprazole is generally considered safer than other PPIs regarding clopidogrel interaction due to less CYP2C19 inhibition, but caution is still advised.
* IV administration is generally reserved for situations where oral intake is not possible.
* Long-term use of PPIs should be re-evaluated periodically to determine if continued therapy is necessary.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making therapeutic decisions.*
